![The Asian Pacific Association for the Study of the Liver [APASL]](http://apasl.info/app-def/S-102/apasl/wp-content/themes/apasl/images/header/img_apasl_logo.png){kind=logo}
Deepest condolences from APASL
It is with great sadness that we inform our community of the passing of Professor Lawrie Powell.
Lawrie made extraordinary contributions to The University of Queensland, the discipline of Hepatology and all related professional organisations. His stellar academic career was built on his unique understanding of the University’s critical place at the intersection of research, teaching and learning, and clinical practice - and the vast potential of this nexus for the creation of new knowledge to improve our understanding of health and disease. And how well he harnessed the power of this space to better understand the pathogenesis and therapy of liver disease, and - particularly his true love - disorders of iron metabolism.
Bridging basic science and clinical medicine to produce clinically relevant research was a passionate, recurrent theme of his academic life. The “Bench to Bedside” catch phrase has been used by many organisations to symbolise their commitment to bridge the gap between science and medicine – but what distinguished Lawrie from others who use this axiom was how well he constructed the bridge. A pivotal part of that construct was his partnership with Professor June Halliday – an outstanding biomedical scientist whose pragmatic skills perfectly complemented the, at times, idealistic positioning of Lawrie. Lawrie and June, with Professor Graham Cooksley established Australia’s first Academic Liver Unit at Royal Brisbane Hospital, Queensland. The Liver Unit attracted numerous scholars – both science-based and medically qualified from all over the country and overseas. It was an inspirational environment in which to study and was the academic birthplace of at least eight current professors. Many more PhD students and countless clinical trainees benefited from Lawrie’s supervision and guidance.
Lawrie’s international reputation was extraordinary. Hepatologists throughout the world were in awe of Lawrie’s contributions which were built on his remarkable energy, drive, and unbridled enthusiasm for the discipline. He received awards and distinctions from multiple national liver societies. He was visionary in the profession as illustrated by his founding (with Professor Kunio Okuda of Japan) of the Asian Pacific Association for the Study of the Liver with Lawrie as its inaugural president. He was immensely proud of his role in this Association and was delighted that it fulfilled his dream of being the premier association in the Asian Pacific region to foster teaching, research, and the dissemination of knowledge in all aspects of diseases of the liver and biliary system.
Yet, despite his stellar achievements, his global recognition, his numerous awards - he was at his core a doctor – committed to upholding all the virtues of Hippocrates, deeply admired by his patients and highly respected by his peers. He knew that a medical academic had to be a clinical expert roundly admired by his co-professionals, and whose judgement on difficult cases was sought by colleagues. Lawrie would always claim that clinical and academic excellence were inexorably linked – and that those who chose the academic track had to be first and foremost outstanding clinicians.
There was so much more to Lawrie’s career, with so many lessons for aspiring clinical academics. These few words barely scratch the surface of the breadth of his contributions. However, his rich legacy will live on for generations housed in those who were fortunate to work closely with one of the greatest clinical academics that this country has ever produced.
- Professor Darrell Crawford, APASL Steering Committee
- Professor Shiv Kumar Sarin, APASL Steering Committee
- Professor Masao Omata, APASL Steering Committee
- Professor Han Chieh Lin, APASL Steering Committee
APASL Annual Meeting 2023 in Taipei
The next APASL Annual Meeting will be held in Taipei!
Please check the link below.
The deadline of abstract submission has been extended to Oct. 31!
Future Meetings
HCC：Clinical and basic research
Date: September 1-3, 2022(On-demand presentation term: until September 30, 2022) City: Takamatsu, Japan President: Dr. Tsutomu Masaki |
 |
APASL STC on Critical Care in Hepatology: ACLF
Date: September 16-18, 2022 City: Wuhan, China President: Dr. Qin Ning Website: http://www.apaslstc2022wh.com |
 |
APASL STC on Hepatotoxicity
Date: September 23-25, 2022 City: Istanbul, Turkey President: Dr. Ibrahim Halil Bahcecioglu Website: https://apaslturkey2022.org/en |
 |
APASL STC on NAFLD/NASH: Non-Infection Epidemic in XXI
Date: October 6-8, 2022 City: Yerevan, Armenia President: Dr. Hasmik Ghazinian Website: to be announced. |
 |
APASL STC on Image-guided Interventions in Liver Diseases
Date: October 21-23, 2022 City: Guangzhou, China President: Dr. Jinjun Chen Website: www.apaslstc2022gz.com |
 |
APASL Annual Meeting 2023
Date: February 15-19, 2023 City: Taipei, Taiwan President: Dr. Han-Chieh Lin Website: https://www.apasl2023.tw |
 |
APASL STC on Advances in the Prevention and Management of Liver Cirrhosis and Its Complication
Date: Spring, 2023 City: Manila, Philippines President: Dr. Ian Homer Y. Cua Website: to be announced. |
APASL Oncology 2023
Date: October 27-28, 2023 City: Sendai, Japan President: Dr. Yoshiyuki Ueno Website: http://apasl-oncology2023.org/ |
 |
APASL Annual Meeting 2024
Date: March 27-31, 2024 City: Tokyo, Japan President: Dr. Shuichiro Shiina Website: https://www.apasl2024kyoto.org/ |
 |
APASL Guidelines
APASL Guidelines for HCC -”Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update” (Hepatol Int 2017; 11: 317-370)
*This APASL Guideline can be downloaded by clicking below.
APASL Guidelines for HBV -"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update" (Hepatol Int 2016; 10:1–98)
*This APASL Guideline can be downloaded by clicking below.
APASL Guidelines for HCV -”APASL consensus statements and recommendation for hepatitis C prevention, epidemiology, and laboratory testing” (Hepatol Int 2016 10:681–701)
*This APASL Guideline can be downloaded by clicking below.
APASL Guidelines for HCV -”APASL consensus statements and recommendation on treatment of hepatitis C” (Hepatol Int 2016 10:702–726)
*This APASL Guideline can be downloaded by clicking below.
APASL Guidelines for Acute-on-chronic Liver Failure -”Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014” (Hepatol Int 2014; 8: 453-471)
*This APASL Guideline can be downloaded by clicking below.
APASL Guidelines for Fibrosis -”Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL)” (Hepatol Int 2009; 3: 323-333)
*This APASL Guideline can be downloaded by clicking below.
APASL consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis a 2016 update (Hepatol Int 2017 11:1–30)
*This APASL Guideline can be downloaded by clicking below.
APASL Guidelines for IPH -”Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment” (Hepatol Int 2007; 1: 398-413)
*This APASL Guideline can be downloaded by clicking below.
APASL Guidelines for Variceal Bleeding -”Primary prophylaxis of gastroesophageal variceal bleeding: consensus recommendations of the Asian Pacific Association for the Study of the Liver” (Hepatol Int 2008; 2: 429-439)
*This APASL Guideline can be downloaded by clicking below.